A single-arm, open-label, multicenter phase II trial (CheckMate 172) of nivolumab (NIVO) safety in European patients (pts) with advanced melanoma (MEL) who have progressed after ipilimumab therapy (IPI).

被引：0
|
作者：
Schadendorf, Dirk
Ascierto, Paolo Antonio
Espinosa, Enrique
Haanen, John B. A. G.
Hermann, Frank
Nathan, Paul D.
机构：
[1] Univ Hosp Essen, Essen, Germany
[2] Ist Nazl Tumori Fdn Pascale, Naples, Italy
[3] Univ Autonoma Madrid, Hosp Univ La Paz, Madrid, Spain
[4] Netherlands Canc Inst, Amsterdam, Netherlands
[5] Bristol Myers Squibb, Munich, Germany
[6] Mt Vernon Canc Ctr, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS9083
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Nivolumab (NIVO) safety in patients with advanced melanoma (MEL) who have progressed on or after ipilimumab (IPI): A single-arm, open-label, multicenter, phase II study (CheckMate 172).
    Ascierto, Paolo Antonio
    Demidov, Lev V.
    Garbe, Claus
    Lorigan, Paul
    Gogas, Helen
    Hoeller, Christoph
    Haanen, John B. A. G.
    Espinosa, Enrique
    Guren, Tormod Kyrre
    Munoz-Couselo, Eva
    Rorive, Andree
    Rutkowski, Piotr
    Dummer, Reinhard
    Carneiro, Ana
    Hospers, Geke
    Hermann, Frank
    Jiang, Joel
    Schadendorf, Dirk
    Nathan, Paul D.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172)
    Schadendorf, Dirk
    Ascierto, Paolo A.
    Haanen, John
    Espinosa, Enrique
    Demidov, Lev
    Garbe, Claus
    Guida, Michele
    Lorigan, Paul
    Chiarion-Sileni, Vanna
    Gogas, Helen
    Maio, Michele
    Fierro, Maria Teresa
    Hoeller, Christoph
    Terheyden, Patrick
    Gutzmer, Ralf
    Guren, Tormod K.
    Bafaloukos, Dimitrios
    Rutkowski, Piotr
    Plummer, Ruth
    Waterston, Ashita
    Kaatz, Martin
    Mandala, Mario
    Marquez-Rodas, Ivan
    Munoz-Couselo, Eva
    Dummer, Reinhard
    Grigoryeva, Elena
    Young, Tina C.
    Nathan, Paul
    EUROPEAN JOURNAL OF CANCER, 2019, 121 : 144 - 153
  • [3] Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)
    Nathan, Paul
    Ascierto, Paolo A.
    Haanen, John
    Espinosa, Enrique
    Demidov, Lev
    Garbe, Claus
    Guida, Michele
    Lorigan, Paul
    Chiarion-Sileni, Vanna
    Gogas, Helen
    Maio, Michele
    Fierro, Maria Teresa
    Hoeller, Christoph
    Terheyden, Patrick
    Gutzmer, Ralf
    Guren, Tormod K.
    Bafaloukos, Dimitrios
    Rutkowski, Piotr
    Plummer, Ruth
    Waterston, Ashita
    Kaatz, Martin
    Mandala, Mario
    Marquez-Rodas, Ivan
    Munoz-Couselo, Eva
    Dummer, Reinhard
    Grigoryeva, Elena
    Young, Tina C.
    Schadendorf, Dirk
    EUROPEAN JOURNAL OF CANCER, 2019, 119 : 168 - 178
  • [4] Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): Results from a phase II study (CheckMate 172).
    Schadendorf, Dirk
    Ascierto, Paolo Antonio
    Haanen, John B. A. G.
    Espinosa, Enrique
    Demidov, Lev V.
    Garbe, Claus
    Lorigan, Paul
    Gogas, Helen
    Hoeller, Christoph
    Guren, Tormod Kyrre
    Rorive, Andree
    Rutkowski, Piotr
    Munoz-Couselo, Eva
    Dummer, Reinhard
    Carneiro, Ana
    Hospers, Geke
    Grigoryeva, Elena Borisovna
    Bhore, Rafia
    Nathan, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [5] Safety profile of nivolumab (NIVO) and ipilimumab (IPI) combination therapy in patients (pts) with advanced melanoma (MEL)
    Sznol, M.
    Ferrucci, P. F.
    Hogg, D.
    Atkins, M.
    Wolter, P.
    Guidoboni, M.
    Lebbe, C.
    Kirkwood, J.
    Schachter, J.
    Daniels, G.
    Hassel, J.
    Cebon, J.
    Gerritsen, W.
    Atkinson, V.
    Thomas, L.
    McCaffrey, J.
    Power, D.
    Jiang, J.
    Hodi, F. S.
    Wolchok, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [6] An open-label, randomized, phase 2 study of nivolumab (NIVO) given sequentially with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 064)
    Hodi, F. S.
    Gibney, G.
    Sullivan, R.
    Sosman, J. A.
    Slingluff, C. L., Jr.
    Lawrence, D. P.
    Logan, T. F.
    Schuchter, L. M.
    Nair, S.
    Fecher, L.
    Buchbinder, E.
    Ruisi, M.
    Kong, G.
    Horak, C.
    Weber, J. S.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S721 - S721
  • [7] A multi-center phase II open-label study (CheckMate 204) to evaluate safety and efficacy of nivolumab (NIVO) in combination with ipilimumab (IPI) followed by NIVO monotherapy in patients (pts) with melanoma (MEL) metastatic to the brain.
    Margolin, Kim Allyson
    Tawbi, Hussein Abdul-Hassan
    Ernstoff, Marc S.
    Hodi, F. Stephen
    McDermott, David F.
    Edwards, Robin
    Avila, Alexandre
    Atkins, Michael B.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [8] Overall survival in patients with advanced melanoma (MEL) who discontinued treatment with nivolumab (NIVO) plus ipilimumab (IPI) due to toxicity in a phase II trial (CheckMate 069).
    Hodi, F. Stephen
    Postow, Michael Andrew
    Chesney, Jason Alan
    Pavlick, Anna C.
    Robert, Caroline
    Grossmann, Kenneth F.
    McDermott, David F.
    Linette, Gerald P.
    Meyer, Nicolas
    Giguere, Jeffrey K.
    Agarwala, Sanjiv
    Shaheen, Montaser F.
    Ernstoff, Marc S.
    Minor, David R.
    Salama, April K.
    Taylor, Matthew H.
    Ott, Patrick Alexander
    Jiang, Joel
    Gagnier, Paul
    Wolchok, Jedd D.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [9] Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study
    Namikawa, Kenjiro
    Kiyohara, Yoshio
    Takenouchi, Tatsuya
    Uhara, Hisashi
    Uchi, Hiroshi
    Yoshikawa, Shusuke
    Takatsuka, Sumiko
    Koga, Hiroshi
    Wada, Naoko
    Minami, Hironobu
    Hatsumichi, Masahiro
    Asada, Suguru
    Namba, Yoshinobu
    Yamazaki, Naoya
    EUROPEAN JOURNAL OF CANCER, 2018, 105 : 114 - 126
  • [10] Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067).
    Wolchok, Jedd D.
    Chiarion-Sileni, Vanna
    Gonzalez, Rene
    Rutkowski, Piotr
    Grob, Jean Jacques
    Cowey, C. Lance
    Lao, Christopher
    Schadendorf, Dirk
    Ferrucci, Pier Francesco
    Smylie, Michael
    Dummer, Reinhard
    Hill, Andrew
    Haanen, John B. A. G.
    Maio, Michele
    McArthur, Grant A.
    Walker, Dana
    Jiang, Joel
    Horak, Christine E.
    Larkin, James M. G.
    Hodi, F. Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345